Interesting that they are using it in Australia. There are headwinds at the moment with China doing the lockdown thing at Russia doing their special military operation. Hopefully the momentum in other places keeps up.
Highlights • Product revenues up 48% YOY in a further difficult COVID year • SUS units/revenues up 42% YOY with China market the key contributor • TruScreen cervical cancer screening device installations increase by 24% YOY • First sales recorded in Eastern Europe • COGA trial completed with outstanding results, and National Pricing Approval achieved in China • Firmware upgrade improves cybersecurity and reduces maintenance costs • Decision to book a provision for impairment of remaining non-current assets given macro-economic uncertainty
Certainly a slow horse to get out of the starting blocks.
Wording doesn't give the positive vibe of huge growth prospects as previous announcements have implied. They have had solid growth which is impressive considering the market, one might expect it doesn't just plateau even with the ongoing Covid-19 shutdown in China. Certainly not disappointed with the result, more the future dampening of growth eluded to.
Cash will be tight in 12 months time, so another capital raise is on the cards. China sorting their Covid regulations could be the game changer, timing on this is anyones guess. The crowd won't throw cash unless there is growth prospects.
Originally Posted by Stock888
Reply With Quote
Bookmarks